Results 131 to 140 of about 56,406 (298)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. [PDF]

Cancers (Basel), 2022
Jørgensen JT, Mollerup J.
europepmc   +1 more source

On faint companions in the close environment of star-forming dwarf galaxies. Possible external star formation triggers ?

, 2001
We have searched for companion galaxies in the close environment of 98 star-forming dwarf galaxies (SFDGs) from field and low density environments, using the NASA Extragalactic Database.
Campos-Aguilar, Campos-Aguilar, Davies, Doublier, Dultzin-Hacyan, Elmegreen, French, Garcia, Gerola, Grogin, Guzmán, Hashimoto, J. Iglesias-Páramo, J. M. Vílchez, K. G. Noeske, K. J. Fricke, Kennicutt, Kennicutt, Kraan-Korteweg, Laurikainen, Lee, Lindner, Loveday, Marinoni, Marlowe, McAlpine, McAlpine, McAlpine, McAlpine, McAlpine, Méndez, Méndez, Odewahn, P. Papaderos, Papaderos, Pilyugin, Popescu, Pustilnik, Pustilnik, Rosenberg, Salzer, Salzer, Salzer, Savage, Schneider, Shull, Taylor, Taylor, Taylor, Telles, Telles, Terlevich, Thuan, Thuan, Tully, Vennik, Vílchez, Vílchez, Walter, Wilcots, Zaritsky   +60 more
core   +1 more source

The Value of Companion Diagnostics

The Journal of Applied Laboratory Medicine, 2021
Bharathi, Vennapusa, Guadalupe, Manriquez, Michael, Lynch, Stella, Redpath   +3 more
openaire   +2 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

ImmunoPET imaging of Trop2 in patients with solid tumours

EMBO Molecular Medicine
Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various ...
Wei Huang, You Zhang, Min Cao, Yanfei Wu, Feng Jiao, Zhaohui Chu, Xinyuan Zhou, Lianghua Li, Dongsheng Xu, Xinbing Pan, Yihui Guan, Gang Huang, Jianjun Liu, Fang Xie, Weijun Wei   +14 more
doaj   +1 more source

X-ray Variability in the Young Massive Triple theta2 Ori A

, 2006
Massive stars rarely show intrinsic X-ray variability. The only O-stars credited to be intrinsically variable are theta1 Ori C due to effects from magnetic confinement of its wind, and theta2 Ori A suspected of similar activity.
Aikman G. C. L., Babel J., Barbon R., Bernacca P. L., Claude R. Canizares, David P. Huenemoerder, Donati J.-F., Donati J.-F., Feldmeier A., Feldmeier A., Gabriel A. H., Gottwald M., Kashyap V., Kazunori Ishibashi, Norbert S. Schulz, Paola Testa, Prilutskii O. F., Schulz N. S.   +17 more
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer

Frontiers in Oncology
Background and objectiveAs the healthcare industry evolves towards precision medicine, methods to assess the value of integrating companion diagnostics in clinical practice through adequate reimbursement levels are becoming essential.
Silviya Nikolova, Wenkang Ma, Gurdeep S. Sagoo, Yogesh Punekar, Elizabeth Sheppard   +4 more
doaj   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source